Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
760estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-01 | actual | When the study began enrolling |
| Primary completion | 2025-11-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Triple Negative Breast Cancer
Intervention
- Drug: No drug
Primary outcomes
what the primary-completion date above is the date OFTreatment sequencing before the diagnosis of advanced, metastatic TNBC (i.e., all treatments received for early TNBC if initially diagnosed with earlier-stage disease)
measured From date of initial diagnosis of early TNBC (if applicable) until diagnosis date of advanced, metastatic TNBC, up to approximately 15 months
Treatment sequencing on or after the diagnosis date for advanced, metastatic TNBC
measured From date of initial diagnosis of advanced, metastatic TNBC until end of follow-up, up to approximately 15 months
Real-world disease-free interval (rwDFI)
measured From the completion of treatment with curative intent (either date of breast tumor surgery or date of last dose of systemic therapy (whichever occurred last) and the first local or distant disease recurrence date, up to approximately 15 months
Clinician-defined real-world progression-free survival (rwPFS)
measured From the start of each line of therapy until end of follow up, up to approximately 15 months
Overall survival
measured From the start of each line of therapy until end of follow-up, up to approximately 15 months
Occurrence of clinical events of interest
measured From the start of each line of therapy until end of follow-up, up to approximately 15 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed